Tag: BioTech

 Schizophrenia affects 1% of the US population but imposes a hefty economic burden of $176.3 billion each year made up of healthcare costs, lost tax… [Read More]

Clinical stage biotechnology company, Lipella Pharmaceuticals (Nasdaq: LIPO) has been granted a Type C meeting request by the FDA. The company expects to meet with… [Read More]

Shares in Nutriband (Nasdaq: NTRB) climbed nearly 50% in morning trading on Thursday after the company outlined its planned clinical and regulatory path for its… [Read More]

Privately-held company, Intelligent Scopes Corporation, specializes in developing state-of-the-art image enhancement and precision AI software solutions for gastroenterology and urology. This month, the company announced… [Read More]

Biopharmaceutical company, Axsome Therapeutics (Nasdaq: AXSM), has announced topline results from its CRESCENDO survey of patients with narcolepsy type 1 receiving treatment, demonstrating high rates… [Read More]

Immuno-pharma company, AIM ImmunoTech (NYSE American: AIM) has published a new data analysis from a long-term Early Access Program studying the company’s drug Ampligen® (rintatolimod)… [Read More]

Privately-held biotechnology company, Axial Therapeutics, is investigating the gut-brain connection as it advances a treatment for Autism Spectrum Disorder (ASD). The company’s lead product candidate,… [Read More]

Anavex Life Sciences (Nasdaq: AVXL) has screened the first patient in its Phase 2 clinical study of ANAVEX®3-71 for the treatment of schizophrenia, ahead of… [Read More]

BioNxt Solutions Inc. (OTCQB: BNXTF) has completed a comparative pharmacokinetic (PK) study of its oral dissolvable film (ODF) based proprietary Cladribine product for the treatment… [Read More]

Biotech companies launching IPOs in the first quarter of 2024 have been largely met with enthusiasm and optimism from investors. The first two months of… [Read More]

Late clinical-stage biopharmaceutical company, Athira Pharma, Inc. (Nasdaq: ATHA), has presented new clinical data highlighting the therapeutic potential of fosgonimeton at the AD/PD™ 2024 International… [Read More]

Australian biotechnology company, Immuron Limited (Nasdaq: IMRN) has announced positive interim topline results from its study of Travelan® in preventing moderate to severe diarrhea following… [Read More]